Riad Mishlawi Purchases 736 Shares of Hikma Pharmaceuticals PLC (LON:HIK) Stock

Hikma Pharmaceuticals PLC (LON:HIK) insider Riad Mishlawi acquired 736 shares of the stock in a transaction that occurred on Tuesday, May 7th. The stock was acquired at an average cost of GBX 1,979 ($24.86) per share, for a total transaction of £14,565.44 ($18,298.29).

Hikma Pharmaceuticals Trading Down 0.2 %

Shares of HIK opened at GBX 1,970 ($24.75) on Thursday. The company has a debt-to-equity ratio of 53.92, a current ratio of 1.57 and a quick ratio of 1.27. Hikma Pharmaceuticals PLC has a 12 month low of GBX 1,711 ($21.49) and a 12 month high of GBX 2,222 ($27.91). The stock’s 50-day moving average is GBX 1,877.74 and its two-hundred day moving average is GBX 1,863.02. The stock has a market cap of £4.37 billion, a PE ratio of 2,900.00, a P/E/G ratio of 2.38 and a beta of 0.44.

Hikma Pharmaceuticals Increases Dividend

The company also recently disclosed a dividend, which was paid on Friday, May 3rd. Shareholders of record on Thursday, March 21st were issued a $0.47 dividend. The ex-dividend date was Thursday, March 21st. This represents a yield of 1.86%. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. Hikma Pharmaceuticals’s payout ratio is currently 8,382.35%.

Wall Street Analysts Forecast Growth

HIK has been the topic of several recent analyst reports. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 ($25.13) price objective on shares of Hikma Pharmaceuticals in a research note on Thursday, April 25th. Barclays reiterated an “equal weight” rating and set a GBX 2,000 ($25.13) target price on shares of Hikma Pharmaceuticals in a research report on Tuesday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 2,068.75 ($25.99).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.